BGC638
BGC638 is a thymidylate synthase inhibitor with a Ki value of 0.24 nM. BGC638 binds to α-FR with high affinity and enters cells via receptor-mediated endocytosis, thereby potently inhibiting thymidylate synthase to block DNA synthesis and ultimately induce apoptosis. BGC638 is applicable to studies related to α-FR-overexpressing tumors and epithelial carcinomas (ovarian cancer and endometrial cancer).
For research use only. We do not sell to patients.
- CAS No.: 416852-27-2
- Formula: C32H33N5O9
- Molecular Weight:631.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L1210 | IC50 |
260 nM
|
Cell growth inhibition against mouse L1210 (RFC+/α-FR-) cells assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
Cell growth inhibition against mouse L1210 (RFC+/α-FR-) cells assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
|
16357184 |
| L1210 (1565) | IC50 |
2100 nM
|
Cell growth inhibition against mouse L1210-1565 (RFC-/α-FR-) cells assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
Cell growth inhibition against mouse L1210-1565 (RFC-/α-FR-) cells assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
|
16357184 |
| L1210 | IC50 |
0.40 nM
|
Cell growth inhibition against mouse L1210-FBP (RFC-/α-FR+) cells assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
Cell growth inhibition against mouse L1210-FBP (RFC-/α-FR+) cells assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
|
16357184 |
| L1210 | IC50 |
300 nM
|
Cell growth inhibition against mouse L1210-FBP (RFC-/α-FR+) cells with co-addition of 1 μM folic acid, assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
Cell growth inhibition against mouse L1210-FBP (RFC-/α-FR+) cells with co-addition of 1 μM folic acid, assessed via cell counting with continuous exposure until growth endpoint corresponding to ~4 population doublings.
|
16357184 |
| A-431 | IC50 |
0.81 μM
|
Cell growth inhibition against human A431 (α-FR-negative) cells assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human A431 (α-FR-negative) cells assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| A-431 | IC50 |
0.97 μM
|
Cell growth inhibition against human A431 (α-FR-negative) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human A431 (α-FR-negative) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| A-431 | IC50 |
0.0028 μM
|
Cell growth inhibition against human A431-FBP (α-FR-overexpressing) cells assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human A431-FBP (α-FR-overexpressing) cells assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| A-431 | IC50 |
0.49 μM
|
Cell growth inhibition against human A431-FBP (α-FR-overexpressing) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human A431-FBP (α-FR-overexpressing) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| KB | IC50 |
0.0036 μM
|
Cell growth inhibition against human KB (α-FR-overexpressing) cells assessed via cell counting with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human KB (α-FR-overexpressing) cells assessed via cell counting with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| KB | IC50 |
0.39 μM
|
Cell growth inhibition against human KB (α-FR-overexpressing) cells with co-addition of 1 μM folic acid, assessed via cell counting with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human KB (α-FR-overexpressing) cells with co-addition of 1 μM folic acid, assessed via cell counting with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| IGROV-1 | IC50 |
0.070 μM
|
Cell growth inhibition against human IGROV-1 (low α-FR-expressing) cells assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human IGROV-1 (low α-FR-expressing) cells assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| IGROV-1 | IC50 |
0.93 μM
|
Cell growth inhibition against human IGROV-1 (low α-FR-expressing) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human IGROV-1 (low α-FR-expressing) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 96-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| JEG-3 | IC50 |
0.26 μM
|
Cell growth inhibition against human JEG-3 (very low α-FR-expressing) cells assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human JEG-3 (very low α-FR-expressing) cells assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
| JEG-3 | IC50 |
0.61 μM
|
Cell growth inhibition against human JEG-3 (very low α-FR-expressing) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
Cell growth inhibition against human JEG-3 (very low α-FR-expressing) cells with co-addition of 1 μM folic acid, assessed via MTT assay with continuous 72-hour exposure in folate-free media supplemented with 20 nM leucovorin.
|
16357184 |
In Vitro
BGC638 potently inhibits the growth of α-FR-overexpressing tumor cell lines in vitro, with an IC50 of 3 nM[1].
BGC 638 (72-96 h) inhibits cell proliferation in A431, A431-FBP, KB, IGROV-1, JEG-3, L1210, L1210-1565, and L1210-FBP cells[2].
BGC638 potently inhibits isolated L1210 thymidylate synthase via a mixed non-competitive mechanism, with a Ki value of 0.24 nM. It binds to α-FR on mouse L1210-FBP cells, with a relative affinity of 66% that of folic acid[2].
BGC 638 (30 nM; 1-16 h) inhibits thymidylate synthase activity in situ in KB cells[2].
BGC 638 (0.03-1 µM; 120 h) significantly reduces the number of adherent cells, inhibits cell growth, and induces apoptosis in JEG-3 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:JEG-3 cells
-
Concentration:0.03, 0.2, 1 µM
-
Incubation Time:120 h
-
Result:Reduced the number of attached cells by slightly more than 50% at concentrations as low as 0.03 µM, and by approximately 90% at 0.2 µM, with 50% of the total cells detaching and displaying apoptotic morphology.
Parmacokinetics
| Species | Dose | Route | AUClast | Cmax | T1/2 | CL | Vss |
|---|---|---|---|---|---|---|---|
| Mice[1] | 3 μM | i.v. | 149 μM·h | 256 μM | 4 h | 1.05 L/h/kg | 1.87 L/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCR nude mice (female, 6-10 weeks of age, folate-free diet for ≥14 days, KB tumor xenograft transplanted, tumor grown to ~250 mm3)[2]
-
Dosage:100 mg/kg
-
Administration:i.p.; single dose; 24 h
-
Result:Specifically and significantly increased the uptake of the marker [125I]dUrd in KB tumor tissue (representing inhibition of thymidylate synthase).
Showed no significant increase in the uptake of [125I]dUrd in normal tissues such as blood, liver, spleen, kidney, stomach, small bowel, and large bowel, demonstrating extremely high tumor selectivity.
Chemical Information
-
CAS No. 416852-27-2
-
Molecular Weight 631.64
-
Formula C32H33N5O9
-
SMILES
N(CC#C)([C@@H]1C=2C(=CC3=C(C2)C(=O)N=C(C)N3)CC1)C4=CC=C(C(N[C@@H](CCC(N[C@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)